Zimbabwe has turned down a significant American health deal worth 367 million US dollars (£272m) spanning five years due to the United States' insistence on sensitive biological samples.
This move became public following a official document from December was leaked, which showed President Emmerson Mnangagwa believed the agreement was "skewed".
A government representative later explained that the United States was demanding access to health data for scientific study and commercial purposes but refused to guarantee the resulting advantages from future treatments.
"We must now begin the difficult and regrettable task of ending our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had furnished more than $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has urged continued negotiations to secure a deal agreeable to both sides so the nation's vital HIV programme can be sustained.
Broader Background
This development comes after a similar case in neighbouring Kenya, where a court suspended a similar health funding agreement after concerns were filed about the security of Kenyans' medical information.
Since returning to the presidency last year, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
The agency had overseen aid for the American government, but Trump stated its expenditure was "inefficient" and his government was pursuing direct bilateral deals to enhance openness and responsibility.
According to statements, 16 African countries have to date signed these new agreements, representing over $18.3bn of fresh investment.
Details of the Rejected Deal
The funds for Zimbabwe was intended to funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this cooperation could have provided immense benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on HIV treatment via US-supported initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to provide its genetic material and health information indefinitely, without any equivalent assurance of benefiting from any scientific breakthroughs – like new medicines or tests – that might result from that provided information," his statement read.
"Effectively, our country would supply the raw materials for scientific discovery with no certainty that the resulting innovations would be available to our citizens if a new health crisis emerge."
Sovereignty and Global Health
He also pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were disrupting structures previously established through the international health agency.
Mangwana cited its Pandemic Benefit-Sharing framework designed to deal with potential global health emergencies.
"This mechanism is intended to ensure that when a country provides its samples, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised solely by those with the resources to create them."
The government's concerns regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We welcome further discussions with our American counterparts on how future co-operation could be arranged in a way that respects the sovereignty and interests of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but suggested that talks need to persist given that much of the nation's HIV programmes depended on international support.
"If technical issues arise, such as those relating to data governance or agreement terms, these can often be addressed via detailed discussion and mutually agreed protections," it added.
The situation emphasises the continuing tensions between receiving much-needed international aid and protecting national sovereignty in an ever more data-driven world.